PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SELADELPAR IN SUBJECTS WITH HEPATIC IMPAIRMENT

被引：0
|
作者：
Mao, Z.
Martin, Robert
Steinberg, Alexandra
Rohane, Patricia
Nguyen, Jaidyn
Standen, Mary
Boudes, Pol
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1476
引用
收藏
页码：S1320 / S1320
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics, safety, and tolerability of seladelpar in subjects with hepatic impairment
    Mao, Lily
    Martin, Robert
    Steinberg, Alexandra
    Rohane, Patricia
    Nguyen, Jaidyn
    Standen, Mary
    Boudes, Pol
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E402 - E402
  • [2] Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
    Baekdal, Tine A.
    Thomsen, Mette
    Kupcova, Viera
    Hansen, Cilie W.
    Anderson, Thomas W.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (10): : 1314 - 1323
  • [3] Pharmacokinetics and tolerability of semaglutide in subjects with hepatic impairment
    Arold, G.
    Kupcova, V.
    Jensen, L.
    Kvist, T.
    Pettersson, J.
    Hjerpsted, J.
    [J]. DIABETOLOGIA, 2017, 60 : S380 - S381
  • [4] Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment
    Ferri, Nicola
    De Martin, Sara
    Stuart, James
    Traversa, Sergio
    Mattarei, Andrea
    Comai, Stefano
    Folli, Franco
    Pappagallo, Marco
    Guidetti, Clotilde
    Inturrisi, Charles E.
    Manfredi, Paolo L.
    [J]. DRUGS IN R&D, 2024, 24 (02) : 341 - 352
  • [5] Pharmacokinetics and tolerability of oral semaglutide in subjects with hepatic impairment
    Sondergaard, F. L.
    Baekdal, T. A.
    Kupcova, V.
    Thomsen, M.
    Anderson, T. W.
    [J]. DIABETOLOGIA, 2017, 60 : S362 - S362
  • [6] Pharmacokinetics and Tolerability of Oral Semaglutide in Subjects with Hepatic Impairment
    Thomsen, Mette
    Baekdal, Tine A.
    Kupcova, Viera
    Sonder-Gaard, Flemming L.
    Anderson, Thomas W.
    [J]. DIABETES, 2017, 66 : A318 - A318
  • [7] Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
    Dayal, Satish
    Aluri, Jagadeesh
    Hall, Nancy
    Filippov, Gleb
    Moline, Margaret
    Reyderman, Larisa
    Landry, Ishani
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (02):
  • [8] Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment
    Jamieson, Brian D.
    Ciric, Sabrina
    Fernandes, Prabhavathi
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4379 - 4386
  • [9] Pharmacokinetics and Safety of Teneligliptin in Subjects With Hepatic Impairment
    Halabi, Atef
    Maatouk, Haidar
    Siegler, Karl Ernst
    Faisst, Nadja
    Hinrichsen, Holger
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (04): : 290 - 296
  • [10] PHARMACOKINETICS AND SAFETY OF NITAZOXANIDE IN SUBJECTS WITH HEPATIC IMPAIRMENT
    Harisseh, Rania
    Finnegan, Beth
    Thomas, Stephane
    Legry, Vanessa
    Hum, Dean
    Marbury, Thomas C.
    Perry, Robert G.
    Wyatt, David J.
    Addy, Carol
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S1391 - S1391
12345